Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective.

Bevan JS, Newell-Price J, Wass JA, Atkin SL, Bouloux PM, Chapman J, Davis JR, Howlett TA, Randeva HS, Stewart PM, Viswanath A

Clinical endocrinology24 Sept 2007Cited by 38 (Europe PMC)

PMID17892497PMCIDPMC2268964DOI10.1111/j.1365-2265.2007.03044.xPepBankPUB-17892497

Download PDF PubMedAsk about this study

Jump to 6 results

Summary

ObjectiveThe introduction of ready-to-use lanreotide Autogel has presented the possibility of patients receiving their acromegaly treatment at home. The objective of this study was to assess the ability of patients (or their partners) to administer repeat, unsupervised, injections of lanreotide Autogel without compromising efficacy or safety.DesignMulticentre (10 UK regional endocrine centres), open-label, nonrandomised, controlled study. Patients elected either to receive/administer unsupervised home injections after injection technique training (Test group) or continued to receive injections from a healthcare professional (Control group). Patients received monthly injections of lanreotide Autogel at their established dose. Effects were monitored for up to 40 weeks.PatientsThirty patients (15 per treatment group) with acromegaly treated with a stable dose of lanreotide Autogel (60, 90 or 120 mg) for > or = 4 months before screening. Measurements The main outcome measure was the proportion of patients/partners who successfully administered injections throughout the study.ResultsAll Test group patients/partners qualified to administer injections. Fourteen of 15 patients fulfilled all criteria for successful administration of unsupervised injections (95% confidence interval, 70%-99%). Fourteen of 15 Test and 14/15 Control patients maintained growth hormone and IGF-1 control. Local injection tolerability was good for both treatment groups, and safety profiles were similar. All Test group patients continued with unsupervised injections after the study.ConclusionsPatients with acromegaly or their partners were able to administer lanreotide Autogel injections with no detrimental effect on efficacy and safety; therefore, unsupervised home injections are a viable alternative to healthcare professional injections for suitably motivated patients.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialOther
In patients with acromegaly, fourteen of fifteen met all criteria for successful unsupervised lanreotide administration.
In plain wordsIn patients with acromegaly, fourteen of fifteen met all criteria for successful unsupervised lanreotide administration.
Peptide
Lanreotide
Outcome
Not applicableSuccessful unsupervised administration
Study
n = 15
Analysis
Primary
Outcome group
Treatment Administration · Endocrine and hormones
Studied dose
60, 90 or 120 mg monthly · up to 40 weeksAs given in this study (human).
Measurements
Successful administration
14 patients
reported result
Confidence interval
70 to 99%
95% confidence interval
Source sentences
Summary
Fourteen of 15 patients fulfilled all criteria for successful administration of unsupervised injections (95% confidence interval, 70%-99%).
3 context sentences(design, population, supporting numbers)
Summary · context
Multicentre (10 UK regional endocrine centres), open-label, nonrandomised, controlled study.
Summary · context
Patients elected either to receive/administer unsupervised home injections after injection technique training (Test group) or continued to receive injections from a healthcare professional (Control group).
Summary · context
Thirty patients (15 per treatment group) with acromegaly treated with a stable dose of lanreotide Autogel (60, 90 or 120 mg) for > or = 4 months before screening.
Show in the study text Report a problemFND-1789249702
02HumanNon-randomized trialEfficacy outcome
In acromegaly, 14 of 15 patients in the home-injection group and 14 of 15 in the healthcare-professional group maintained growth hormone and IGF-1 control on lanreotide Autogel.
In plain wordsIn acromegaly, 14 of 15 patients in each group kept growth hormone and IGF-1 under control with home or professional lanreotide injections.
Peptide
Lanreotide
Outcome
Not applicableGrowth hormone and IGF-1 control
Study
n = 30
Comparator
Healthcare professional injections
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
60, 90 or 120 mg monthly · up to 40 weeksAs given in this study (human).
Measurements
Patients maintaining GH and IGF-1 control
14 patients
Test group (home injections), of 15
Patients maintaining GH and IGF-1 control
14 patients
Control group (healthcare-professional injections), of 15
Source sentences
Summary
Fourteen of 15 Test and 14/15 Control patients maintained growth hormone and IGF-1 control.
3 context sentences(design, population, supporting numbers)
Summary · context
Multicentre (10 UK regional endocrine centres), open-label, nonrandomised, controlled study.
Summary · context
Patients elected either to receive/administer unsupervised home injections after injection technique training (Test group) or continued to receive injections from a healthcare professional (Control group).
Summary · context
Thirty patients (15 per treatment group) with acromegaly treated with a stable dose of lanreotide Autogel (60, 90 or 120 mg) for > or = 4 months before screening.
Show in the study text Report a problemFND-1789249703
03HumanNon-randomized trialSafety outcome
In acromegaly, local lanreotide injection tolerability was good with both home and professional injections.
In plain wordsIn acromegaly, local lanreotide injection tolerability was good with both home and professional injections.
Peptide
Lanreotide
Outcome
Not applicableLocal injection tolerability
Study
n = 30
Comparator
Healthcare professional injections
Outcome group
Adverse events · Endocrine and hormones
Studied dose
60, 90 or 120 mg monthly · up to 40 weeksAs given in this study (human).
Source sentences
Summary
Local injection tolerability was good for both treatment groups, and safety profiles were similar.
3 context sentences(design, population, supporting numbers)
Summary · context
Multicentre (10 UK regional endocrine centres), open-label, nonrandomised, controlled study.
Summary · context
Patients elected either to receive/administer unsupervised home injections after injection technique training (Test group) or continued to receive injections from a healthcare professional (Control group).
Summary · context
Thirty patients (15 per treatment group) with acromegaly treated with a stable dose of lanreotide Autogel (60, 90 or 120 mg) for > or = 4 months before screening.
Show in the study text Report a problemFND-1789249705
04HumanNon-randomized trialSafety outcome
In acromegaly, lanreotide safety profiles were similar with home and professional injections.
In plain wordsIn acromegaly, lanreotide safety was similar with home and professional injections.
Peptide
Lanreotide
Outcome
Not applicableSafety profile
Study
n = 30
Comparator
Healthcare professional injections
Outcome group
Adverse events · Endocrine and hormones
Studied dose
60, 90 or 120 mg monthly · up to 40 weeksAs given in this study (human).
Source sentences
Summary
Local injection tolerability was good for both treatment groups, and safety profiles were similar.
3 context sentences(design, population, supporting numbers)
Summary · context
Multicentre (10 UK regional endocrine centres), open-label, nonrandomised, controlled study.
Summary · context
Patients elected either to receive/administer unsupervised home injections after injection technique training (Test group) or continued to receive injections from a healthcare professional (Control group).
Summary · context
Thirty patients (15 per treatment group) with acromegaly treated with a stable dose of lanreotide Autogel (60, 90 or 120 mg) for > or = 4 months before screening.
Show in the study text Report a problemFND-1789249706
05HumanNon-randomized trialOther
In patients with acromegaly, all home-injection patients or partners qualified to administer lanreotide injections.
In plain wordsIn patients with acromegaly, all home-injection patients or partners qualified to give lanreotide injections.
Peptide
Lanreotide
Outcome
Not applicableQualification for home injection
Study
n = 15
Outcome group
Treatment Administration · Endocrine and hormones
Studied dose
60, 90 or 120 mg monthly · up to 40 weeksAs given in this study (human).
Source sentences
Summary
All Test group patients/partners qualified to administer injections.
3 context sentences(design, population, supporting numbers)
Summary · context
Multicentre (10 UK regional endocrine centres), open-label, nonrandomised, controlled study.
Summary · context
Patients elected either to receive/administer unsupervised home injections after injection technique training (Test group) or continued to receive injections from a healthcare professional (Control group).
Summary · context
Thirty patients (15 per treatment group) with acromegaly treated with a stable dose of lanreotide Autogel (60, 90 or 120 mg) for > or = 4 months before screening.
Show in the study text Report a problemFND-1789249701
06HumanNon-randomized trialOther
In acromegaly, all home-injection patients continued unsupervised lanreotide injections after the study.
In plain wordsIn acromegaly, all home-injection patients continued unsupervised lanreotide injections after the study.
Peptide
Lanreotide
Outcome
Not applicableContinuation of home injection
Study
n = 15
Outcome group
Treatment Administration · Endocrine and hormones
Studied dose
60, 90 or 120 mg monthly · up to 40 weeksAs given in this study (human).
Source sentences
Summary
All Test group patients continued with unsupervised injections after the study.
3 context sentences(design, population, supporting numbers)
Summary · context
Multicentre (10 UK regional endocrine centres), open-label, nonrandomised, controlled study.
Summary · context
Patients elected either to receive/administer unsupervised home injections after injection technique training (Test group) or continued to receive injections from a healthcare professional (Control group).
Summary · context
Thirty patients (15 per treatment group) with acromegaly treated with a stable dose of lanreotide Autogel (60, 90 or 120 mg) for > or = 4 months before screening.
Show in the study text Report a problemFND-1789249707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT00149188

Somatuline Autogel: Acromegaly Self/Partner Injection Study

Ipsenn = 30Feb 2004 to 24 Aug 2005

Acromegaly

Trial page ClinicalTrials.govUpdated 5 Aug 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.